With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

New milestone achieved in Astellas T-cell engager collaboration: In February 2025, Astellas advanced the second program to GLP toxicology studies, triggering a $5 million milestone payment to CytomX.

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among ...

A study on mice with melanoma found that aspirin lowered TXA2 levels, which freed up T cells and allowed them to fight cancer more effectively. However, the lead scientist stressed that long-term ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Varda Space Industries achieved the first successful commercial space reentry in Australia, a milestone for the industry. Varda's co-founder and president, Delian Asparouhov, joins Josh Lipton on ...

Astellas Pharma (OTCPK:ALPMY) and YASKAWA Electric signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the ...